In a report released today, Alex Arfaei from BMO Capital maintained a Buy rating on Eli Lilly & Co (LLY), with a price target of $129. The company’s shares opened today at $115.58, close to its 52-week high of $119.84.
According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.1% and a 70.5% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Bristol Myers.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $122.89, which is a 6.3% upside from current levels. In a report issued on January 7, Cantor Fitzgerald also maintained a Buy rating on the stock with a $128 price target.
See today’s analyst top recommended stocks >>
Based on Eli Lilly & Co’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $1.15 billion. In comparison, last year the company had a GAAP net loss of $1.66 billion.
Based on the recent corporate insider activity of 130 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
